Table 1. FDA-approved compounds that show inhibition of osteosarcoma cell proliferation.
| Compound | Cytotoxicity (% of control) | |||
|---|---|---|---|---|
| KHOS/NP | MG-63 | D17 | Abrams | |
| 10-Hydroxycamptothecin | 82.0 | 58.0 | 34.9 | 66.8 |
| Cerivastatin | 72.1 | 82.3 | 91.1 | 74.4 |
| Disulfiram | 22.7 | 8.9 | 51.8 | 49.4 |
| Ciclopirox ethanolamine | 35.8 | 20.5 | 25.4 | 40.0 |
| Dequalinium dichloride | 17.2 | 35.2 | 32.2 | 9.9 |
| Puromycin | 95.1 | 90.2 | 93.8 | 70.7 |
| Quinacerine | 47.5 | 28.7 | 21.7 | 21.2 |
| Auranofin | 70.2 | 44.4 | 72.7 | 86.4 |
| Alexidine dihydrochloride | 53.8 | 38.6 | 41.0 | 32.0 |
| Cytarabine | 26.4 | 32.6 | 15.7 | 4.4 |
| Antimycin A-HCl | 32.8 | 27.5 | 48.4 | 42.1 |
| Amantidine | 14.1 | 23.4 | 10.6 | 21.3 |
| Novobiocin a-Na | 19.5 | 26.3 | 20.7 | 27.1 |